GeoVax Labs, Inc. Form 8-K May 03, 2018
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 3, 2018
GEOVAX LABS, INC.

(Exact name of registrant as specified in its charter)

Delaware 000-52091 87-0455038

(State or other jurisdiction of

(Commission File No.) (IRS Employee Identification No.)

incorporation or organization)

Edgar Filing: GeoVax Labs, Inc. - Form 8-K

1900 Lake Park Drive, Suite 380
Smyrna, Georgia 30080
(Address of principal executive offices) (Zip code)
(678) 384-7220
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions.
[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
[] White communications pursuant to state 125 under the Securities Fiet (17 G1R 250.125).
[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12).
[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CAR 240.13(e)-4(c)).
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securitie Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company.
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Edgar Filing: GeoVax Labs, Inc. - Form 8-K

This Form 8-K and other reports filed by GeoVax Labs, Inc. (the "Registrant") from time to time with the Securities and Exchange Commission (collectively the "Filings") contain forward looking statements and information that are based upon beliefs of, and information currently available to, the Registrant's management as well as estimates and assumptions made by the Registrant's management. When used in the Filings the words "anticipate", "believe", "estimate", "expect", "future", "intend", "plan" or the negative of these terms and similar expressions as they relate to the Registrant or the Registrant's management identify forward looking statements. Such statements reflect the current view of the Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the Registrant's industry, operations and results of operations and any businesses that may be acquired by the Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Item 2.02 Results of Operations and Financial Condition

On May 3, 2018 we issued a press release reporting our results of operations for the quarter ended March 31, 2018. A copy of the press release is attached to this Current Report.

Item 9.01 Financial Statements and Exhibits

Exhibit 99.1 Press Release

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 3, 2018

GEOVAX LABS, INC.

By: /s/ Mark W. Reynolds

Edgar Filing: GeoVax Labs, Inc. - Form 8-K

Chief Financial Officer